Loading analysis...
Loading Truth Social...
Loading live updates...
—
S&P 500— —
Nasdaq— —
Dow Jones— —
载入时间机器…
Recent PTGX News Headlines
Latest news coverage for PTGX aggregated from WSJ, Bloomberg, The New York Times, Financial Times, and Google News. Real-time updates, free and ad-free.
- Here's How Much $100 Invested In Protagonist Therapeutics 10 Years Ago Would Be Worth Today
- Protagonist Therapeutics Insider Sold Shares Worth $18,240,568, According to a Recent SEC Filing
- Protagonist Therapeutics at Cantor conference: cash, launches and pipeline
- Protagonist Therapeutics Announces $300 Million Share Repurchase Program
- Protagonist (PTGX) Swings To A Profit As Two Drugs Near Blockbuster Status
- MIMRYLO Approval Triggered $275M Payments for Protagonist (PTGX). Are Royalties the Better Commercial Model?
- Protagonist Therapeutics stock rating maintained at Buy by Clear Street
- Jefferies reiterates Protagonist Therapeutics stock rating on Mimrylo label strength
- Wolfe Research reiterates Protagonist Therapeutics stock rating at outperform By Investing.com
- Wolfe Research reiterates Protagonist Therapeutics stock rating at outperform
- Protagonist Therapeutics, Inc. (PTGX) Discusses FDA Approval of Mimrylo for Erythrocytosis in Polycythemia Vera - Slideshow (NASDAQ:PTGX) 2026-08-31
- J&J granted China nod for oral psoriasis pill developed with Protagonist
- Protagonist Therapeutics CEO Dinesh Patel sells $14.9m in stock
- Protagonist Therapeutics: 'Strong Buy' ICOTYDE FDA Approval And PN-881 Advancement (PTGX)
- Surging Earnings Estimates Signal Upside for Protagonist Therapeutics (PTGX) Stock
PTGX options: max pain, gamma exposure (GEX) & key levels · Search PTGX in the news archive · All tickers
Settings
Appearance
Card Style
Language
Notifications
Live View Style
Trump Truth Social
About
Version
2.6.1
Data Source
r/wallstreetbets
AI Engine
ChatGPT/Gemini/Claude
MCP Server
https://mcp.sellthenews.org/mcp
Contact Us
[email protected]